Bausch Health Companies reports tomorrow with a quietly interesting setup: short interest has climbed 22% over the past month, the ORTEX short score has drifted higher all week, and the stock trades at $4.52 — roughly 38% below the analyst consensus target. The tension is less about squeeze mechanics and more about whether the market believes the Street's case at all.
The positioning picture is less dramatic than the headline short-interest growth suggests. Short interest now runs at about 2.1% of the free float — low in absolute terms, and borrowing remains extremely cheap at 0.57%, a rate that has roughly doubled on the week but remains far from stressed territory. Availability is exceptionally loose at over 1,000%, meaning roughly ten shares are available to borrow for every one already lent out. That is not a borrow squeeze setup. The options market tells a similar story: the put/call ratio has actually eased to 1.55, below its 20-day average of 1.62 — options traders are slightly less defensive than they have been. The ORTEX short score has drifted up from 34.98 to 36.61 over the past nine sessions, a slow grind that reflects the steady accumulation of short shares rather than any sharp tactical move.
The Street's view is uniformly cautious rather than divided. Recent analyst actions — RBC Capital cutting its target to $9 in late April, Barclays trimming to $7 in February — point to a direction of travel: targets coming down while ratings hold at neutral-equivalent levels. No analyst has upgraded the stock. The mean target is $7.30 against a current price of $4.52, implying over 60% upside on paper, but the gap reflects skepticism rather than opportunity: negative book value, a heavy debt load, and an EV/EBITDA of roughly 6x anchor the valuation. Factor scores underline the disconnect — EPS surprise ranks in just the 2nd percentile, and EPS momentum over 30 days sits in the 21st. The bull case rests on Solta Medical's 28% growth and solid Canadian performance; the bear case points to a projected 7% revenue decline by 2027 and ongoing IRA headwinds.
Ownership concentration adds a layer worth noting. Paulson & Co. holds nearly 20% of shares, GoldenTree Asset Management just over 9%, with both unchanged in their most recent filings. That concentration means thin float dynamics even before accounting for the approximately 2% lent short. Two more recent institutional moves stand out: Acadian Asset Management added roughly 2.7 million shares through April, and Geode Capital Management added 2.5 million through May — both modest but directionally constructive. Insider activity has been routine, consisting of stock awards to the EVP and Chief Accounting Officer with tax-withholding sells attached, carrying significance scores of just 1 out of 10.
The two most recent earnings prints offer thin but directionally positive evidence: BHC rose 3% and 1.8% on the day after each of the last two quarterly results. Neither move was large, and the five-day reaction faded to flat or slightly negative both times, suggesting the market takes modest beats as relief rather than a reason to re-rate.
What to watch tomorrow is whether Solta Medical and the Canadian segment can offset the international drag — particularly Latin America — and whether management gives any firmer guidance on IRA-related revenue headwinds into 2027, the single variable most likely to move analyst targets in either direction.
See the live data behind this article on ORTEX.
Open BHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
